Sodium hyaluronate in the treatment of interstitial cystitis

Abstract

Objective To investigate the safety and efficacy of intravesical sodium hyaluronate therapy for the patients with interstitial cystitis (IC). Methods Foryt-six patients with IC were in-volved in this six-month, prospective trial. All the 46 patients received intravesieal sodium hyaluronate therapy, 40 mg/50 ml, once a week for 4 weeks, then once a month for 5 months. Clinical symptoms (micturition frequency per day, maximal micturition volume and odynuria degree score), O'Leary-Sant IC symptom and problem index, and quality of life score were assessed at baseline and then again after 1, 3 and 6 months of treatment. Side effects were recorded. Results The levels of micturition frequency per day at the baseline and after 1, 3 and 6 months of the treatment were 29.96±8.81, 19.91±8.76, 15.63±3.70 and 14.44±8.22, respectively. Compared with the baseline, there were significant differences(P<0.01). The levels of maximal micturition volume at the baseline and after 1, 3 and 6 months of the treatment were 115.51±65.58, 125.73±65.53, 146.07±65.11 and 166.51±64.72 ml, respectively. Compared with the baseline, there were significant differences(P<0.01). The levels of odynuria degree score at the baseline and after 1, 3 and 6 months of the treatment were 6.47±1.31, 4.44±1.29, 3.33±1.30 and 2.13±1.06, respectively. Compared with the base-line, there were significant differences(P<0.01). The levels of O'Leary-Sant IC symptom and prob-lem index at the baseline and after 1, 3 and 6 months of the treatment were 26.60±3.77, 19.53±3.79, 15.13±3.78 and 11.84±3.43, respectively. Compared with the baseline, there were signifi-cant differences(P<0.01). The levels of quality of life score at the baseline and after 1, 3 and 6 months of the treatment were 5.47±0.51, 3.44±0.55, 2.36±0.57 and 2.29±0. 59, respectively. Compared with the baseline, there were significant differences (P<0.01). There was significant difference between 3-month treatment and 1-month treatment in the aspect of life quality score. But there was no significant difference between 6-month treatment and 3-month treatment in the aspect of life quality score. One female patient withdrawled because of liver cancer. The other patients had sta-ble vital sign in the whole treatment. There were no adverse events and bladder irritation after intra-vesical sodium hyaluronate therapy. Conclusion Intravesical sodium hyaluronate therapy can effec-tively relieve clinical symptom of IC and improve IC patients' quality of life and is well tolerated. Key words: Cystitis, interstitial; Sodium hyaluronate